News2021-05-05T09:38:20+00:00

OcellO joins Crown Bioscience! Learn more…

News

1408, 2019

OcellO at AACR-NCI-EORTC Boston: Visit our booth #1628

August 14th, 2019|

OcellO team will be joining AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on the 26-30th October. We look forward to meeting with you ! If you like to set up a one-to-one meeting, you can reach us at [email protected] otherwise come by our booth #1628. Please follow the link for more information about this conference; aacr.org

2603, 2019

Press Release

March 26th, 2019|

OcellO announces two year agreement with Merus to provide in vitro research services for MCLA-158 and other undisclosed Biclonics ® programs LEIDEN, the Netherlands, March. 28, 2019 OcellO B.V., a Contract Research Organisation offering 3D cell based assay services for drug discovery to the pharmaceutical industry, today announced that it entered an agreement to provide in vitro research services to Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, for Merus’ MCLA-158 Biclonics® program and [...]

Heads up for Cinthya Del Angel Zuvirie, OcellO's Associate Scientist, bringing great enthusiasm and passion to set up new and expanding existing organoid models for 3D high-throughput-screening assays.

Meet Hester Bange, OcellO's Senior Scientist, Head of Cystopathic Diseases, who shows that OcellO keeps physiological relevance of models and data-rich read-outs hand to hand, and at the same time creates a motivating environment for scientists to work and grow.

Today we celebrate National #Secretary Day in the Netherlands, and for that, we would like to recognize our office manager Henriette Ouwehand, whose daily support is essential for OcellO's team!

Meet OcellO's Senior Director, Head of Immuno-Oncology Lidia Daszkiewicz whose team is making it possible to test a diverse range of immunotherapies focusing on different immune compartments and targeting diverse cancer indications!

OcellO offers compound testing services using co-cultures of cancer and immune cells. Diverse cultured tumor tissues can be used in these assays. So, can you guess which tumor tissue is in this picture?

Learn more here: https://lnkd.in/eeUkR3w

OcellO created a fully scalable platform for automated handling of organoids and compounds, 3D imaging, and 3D image analysis. The result is a unique screening platform for efficient testing of new drugs and drug combinations in state-of-the-art biological models.

Load More...
Go to Top